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Introduction: Paraneoplastic pruritus is defined as pruritus that occurs before or during the natural evolution of a
hematologic disease. The reported prevalence is 30% in patients with Hodgkin’s lymphoma. The severity of this
pruritus has a very negative impact on patients’ quality of life. Very few studies have been made to examine the
efficacy of pharmacological treatments for this type of pruritus. One drug that appears to be effective in this
respect is off-label aprepitant, a neurokinin 1 receptor antagonist.
Case presentation: A 20-year-old Caucasian woman presented with lateral neck nodes, sweating, and pruritus
and was diagnosed with stage IIB nodular sclerosis Hodgkin’s lymphoma. Throughout this period during the disease
the pruritus was ever-present. Improvement was achieved with some of the chemotherapy treatments, but the
symptom returned when the various treatments were withdrawn due to disease progression or poor tolerance. In
the middle of the seventh year, she was admitted to our hospital with uncontrolled pruritus that resulted in severe
lesions due to scratching. In response, aprepitant (off-label) 80mg/day was added to the chemotherapic treatment
of the pruritus, after studying the various treatment options. She reported a score of 9 on a visual analogue scale
for the pruritus, and a score of 3 on the Eastern Cooperative Oncology Group performance status scale of performance
status. After two weeks of treatment with aprepitant, she reported a score of 5 on the visual analogue scale for the
pruritus, and this improved to a score of 4 in a month, which allowed her to lead a better quality of life, with an Eastern
Cooperative Oncology Group performance status score between 1 and 2.
Conclusions: Several cases and case series have been reported on the use of aprepitant for paraneoplastic pruritus,
but none have referred to its use for Hodgkin’s lymphoma. A prospective study was carried out to evaluate the efficacy
of this drug in refractory pruritus secondary to Sezary syndrome, and other authors have studied the effectiveness of
aprepitant against pruritus, secondary to biological therapy with erlotinib. In our case report, treatment was started
with daily doses of aprepitant 80mg. Pruritus improvement appeared to be attributable exclusively to the
administration of aprepitant.
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Hodgkin’s lymphoma (HL) is a B-cell lymphoprolifera-
tive syndrome that is characterized by the presence of
giant Reed-Sternberg cells. HL accounts for 15 to 20% of
all lymphomas [1]. Although the aetiology of the process
is unknown, it seems to be related to certain genetic fac-
tors and infectious agents such as the Epstein-Barr virus
(EBV). The most frequent clinical manifestation (70 to* Correspondence: jjavier.arenas@gmail.com
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article, unless otherwise stated.80% of cases) is the occurrence of one or more (usually
painless) peripheral lymphadenopathies in supradiaph-
ragmatic lymph node regions [2]. Between 25 and 50%
of patients suffer various associated B symptoms that
include weight loss, drenching night sweats, and fever.
Another typical characteristic is generalized pruritus [1].
Paraneoplastic pruritus is defined as pruritus that
occurs before or during the natural evolution of a
hematologic disease; it is not caused by invasion of the
tumor mass or by compression and disappears after re-
moval of the tumor. The reported prevalence is 30% in
patients with HL and it presents as ichthyosiform skined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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severity of this pruritus has a very negative impact on
patients’ quality of life [4].
Very few studies have been made to examine the effi-
cacy of pharmacological treatments for this type of prur-
itus. One drug that appears to be effective in this respect
is off-label aprepitant, a neurokinin 1 (NK-1) receptor
antagonist that was approved in 2003 for the prevention
of chemotherapy-induced nausea and vomiting, both
acute and delayed. The main ligand of the NK-1 recep-
tor, substance P, has emerged as an important mediator
of the induction and maintenance of pruritus [5]. Fur-
thermore, increased levels of NK-1 have been reported
in the keratinocytes of patients with chronic pruritus [6].
In this paper, we evaluate the use of aprepitant to treat
the paraneoplastic pruritus suffered by a patient with
refractory HL.
Case presentation
A 20-year-old Caucasian woman presented with lateral
neck nodes, sweating, and pruritus and was diagnosed
with stage IIB nodular sclerosis HL. Relevant back-
ground factors included a jaw abscess and an allergy to
vancomycin. Serology revealed only positive EBV. From the
first episode until her death eight years later, several treat-
ments were applied. Firstly, chemotherapy adriamycin-
bleomycin-vinblastine-dacarbazine (ABVD) for six cycles
during the first seven months with complete radiological
response lasting four months. Subsequent treatment in-
volved chemotherapy gemcitabine-dexamethasone-cisplatin
(GDP) for three cycles and ifosfamide-etoposide for two cy-
cles, followed by a hematopoietic progenitor cell transplant,
which achieved a complete response during the second
year. Treatment continued with gemcitabine-vinorelbine
for eight cycles from March to September of the third year,
with a partial response, and everolimus (off-label) 5mg/day
for the following 12 months, which stabilized the illness
and eliminated the B “weight loss, drenching night
sweats, and fever” symptoms. The following treatment
was cyclophosphamide-vincristine-prednisone (CVP)
for two cycles until the beginning of the fifth year of
therapy, with progression. GDP for two cycles was then
re-administered, followed by a cycle of bendamustine
90mg/m2, with progression in both cases. Treatment con-
tinued with gemcitabine-vinorelbine-liposomal doxorubicin
(GVD, off-label) for eight cycles in the middle of the same
year with a partial response and, during the sixth year,
metronomic therapy with cyclophosphamide, vinblastine,
and celecoxib, which stabilized the illness. She was
then included in the clinical trial RV-HL-GOTEL-440
(EUDRACT: 2009-016588-12) which consists of lenali-
domide and metronomic doses of cyclophophamide for
refractory HL patients, but again there was disease
progression, and so treatment was switched to high-dose dexamethasone (40mg/day, four days a week) in
the first months of the seventh year, which obtained a
partial response lasting two months. SNG-35 (brentux-
imab vedotin) which formed part of the laboratory’s
extended-use program, was requested and five doses
were administered, finishing five months later in the
same year due to progression of the disease. Treatment
began with oral etoposide, followed by chemotherapy
with carboplatin and gemcitabine. At the beginning of
the eighth year, she was admitted for palliative symp-
tomatic treatment, beginning with thalidomide and
dexamethasone, but died at the third month due to re-
spiratory failure caused by compression of the airway
by lymphoma.
Throughout this period the pruritus was ever-present.
Improvement was achieved with some of the chemother-
apy treatments, but the symptom returned when the
drugs were withdrawn due to disease progression or
poor tolerance. During the GVD treatment, the pruritus
remained unchanged and during the R-HL-GOTEL-440
trial, she suffered a subjective increase in the itching
sensation, which prevented sleep and caused the ap-
pearance of papulopustular lesions. Treatment with
high-dose dexamethasone produced an improvement
but when it was gradually withdrawn, the pruritus
began to reappear.
In the middle of the seventh year, she was admitted
with pancytopenia and deep vein thrombosis of the left
leg, together with uncontrolled pruritus that resulted in
severe lesions due to scratching. In response, aprepitant
(off-label) at 80mg/day was added to the chemotherapic
treatment of the pruritus, after studying the various
treatment options and the scientific research available.
She reported a score of 9 on a visual analogue scale
(VAS) for the pruritus, and a score of 3 on the Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus scale of performance status. After two weeks of treat-
ment with aprepitant, she reported a score of 5 for
pruritus on the VAS, and this improved to a score of 4
in a month, which allowed her to lead a better quality of
life, with an ECOG level between 1 and 2. The pruritus
remained controlled until she had to be readmitted,
when it returned to VAS 9. Throughout this period, the
lymphoma therapy remained unchanged.
Within the severe context of lymphomas, HL is gener-
ally considered to have a favorable prognosis, with 75%
of patients achieving a cure if appropriate chemotherapy
is received [1]. However, some cases are refractory, such
as the one presented here, in which her age and quality
of life led the healthcare team to consider many types of
therapeutic alternatives. Thus, in this case our patient
received more than 10 different treatment approaches.
Severe paraneoplastic pruritus is a symptom associated
with HL for which there is no specific, effective cure,
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corticosteroids. In the case presented, the severity of the
pruritus seriously affected her quality of life and after
exhausting the standard treatment alternatives, the off-
label use of aprepitant was proposed in a clinical session.
Several cases and case series have been reported on
the use of aprepitant for paraneoplastic pruritus, but
none have referred to its use for HL. A prospective study
was carried out to evaluate the efficacy of this drug in
refractory pruritus secondary to Sezary syndrome, a type
of non-Hodgkin’s lymphoma that primarily affects the
skin and is usually secondary to mycosis fungoides. In
the latter study, 80mg/day aprepitant was administered
for 10 days and then on alternate days. The patients’ im-
provement was assessed on the Dermatology Life Qual-
ity Index (DLQI) and on a VAS. By the end of the study,
a statistically significant reduction in the pruritus was
reflected in both indices (P <0.005) and no adverse ef-
fects were detected [7]. Stander et al. also studied the ef-
fect of a daily dose of aprepitant 80mg/day for 3 to 13
days to treat refractory pruritus in 20 patients with vari-
ous underlying pathologies. Their results also showed a
significant decrease in the VAS (P <0.001), with a re-
sponse being achieved in 80% of the patients [8].
Other authors have studied the effectiveness of aprepi-
tant against pruritus, secondary to biological therapy
with erlotinib, conducting a pilot study and administer-
ing three doses of aprepitant in a week (125mg on the
first day and 80mg for the next two days). This study re-
ported a significant decrease in the pruritus at one week
after starting treatment [9]. Another paper described a case
series of five patients with cutaneous T-cell lymphoma, for
whom the same treatment schedule was prescribed. A re-
sponse was achieved in 80% of these patients, with reduc-
tions in both the DLQI and VAS scores. Although these
differences were not statistically significant, in view of the
small number of patients, they were quantifiable [10].
In our case report, treatment was started with daily
doses of aprepitant 80mg. This produced a marked im-
provement in her quality of life and in the control of the
pruritus, as evidenced by the reduced score on the VAS
scale, from 9 to 5 after two weeks and down to 4 after
one month. This outcome improved her ECOG result,
as a pruritus score of 9 on the VAS significantly affected
her quality of life and forced her to remain in bed for
long periods. This improvement appears to be attribut-
able exclusively to the administration of aprepitant, as
during this period the other aspects of the treatment
remained unchanged.
Our patient did not present any unexpected side ef-
fects that could be related to this drug. In none of the
studies reviewed was any evidence found of adverse re-
actions that might have resulted from the continued use
of aprepitant [7-10].Conclusions
We report the case of a patient whose principal mani-
festation of HL was paraneoplastic pruritus, and how
after several approaches to control it by treating HL, we
finally decided to explore the off-label use of aprepitant.
How aprepitant acts in this type of pruritus is not stud-
ied, but it is supposed that the main ligand of the NK-1
receptor, (substance P) is an important mediator of the
induction and maintenance of pruritus, that an NK-1 re-
ceptor antagonist such as aprepitant could resolve the
symptom.
According to previous publications, aprepitant has
shown efficacy in controlling paraneoplastic pruritus,
although to the best of our knowledge, had never been
used specifically in a case of HL. More studies should
be carried out to show if aprepitant could represent
another option in patients with paraneoplastic pruritus
whose pharmacotherapy is limited.
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